A Phase 1 interventional study of Ritlecitinib in Healthy Volunteers, sponsored by Pfizer. Completed at 1 site in Belgium. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-04-10.
Sponsored by Pfizer · Phase 1, Interventional, and Basic science
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The purpose of this study is to compare if three forms of study medicine (called ritlecitinib) get processed differently in healthy adults.
This study is seeking healthy participants who have:
All participants in this study will receive a ritlecitinib oral dose in three different forms (solution, capsule 1 and capsule 2).
The study will take up to 2.5 months, including the screening period and follow-up phone call. Participants will have to stay at the study clinic for at least 13 days. There will be 4 periods in total for this study. On day 1 of each period, participants will take one form of Riltecitinib without food for the first three periods and with food for the last period. Participants will have blood samples taken both before and after taking ritlecitinib. A follow-up phone call will be made at 28 to 35 days after the last study period.
Ritlecitinib is a covalent and irreversible inhibitor of JAK3 with high selectivity over the other JAK isoforms (JAK1, JAK2, and TYK2). Ritlecitinib also inhibits irreversibly the TEC family kinases with selectivity over the broader human kinome. Treatment with ritlecitinib is expected to inhibit the inflammatory pathways mediated by IL 7, IL 15 and IL 21, all implicated in UC, CD, AA, RA, and vitiligo and therefore under development in these indications. Moreover, due to lack of activity against the other JAK isoforms, ritlecitinib is expected to spare immunoregulatory cytokines such as IL 10, IL 27 and IL 35, which are critical to the maintenance of immunosuppressive functions and immune homeostasis.
This study aims to investigate the pharmacokinetics (PK) and relative bioavailability of 2 new modified release (MR) capsule formulations of ritlecitinib, MR1 (release duration: 6-8 hours) and MR2 (release duration:13 15 hours) as single doses in fasted and fed conditions.
This is a single dose, open-label, randomized, 4-period, 6-sequence crossover study in a single cohort of approximately 12 healthy participants randomized to one of the sequences (containing 1 solution and 2 modified release [MR1 and MR2] capsule formulations of ritlecitinib) described in the table below. The first 3 periods are under fasted condition and the fourth period is under fed condition to investigate the effect of food on the PK of MR1 and MR2.
For a given participant, the total study duration from screening to follow-up phone call will be between approximately 8 to 11 weeks.
Screening will occur within 28 days prior to the first dose of the study intervention. Each participant will go through Periods 1 through 4 and dosing in each treatment period will be separated by at least 3 days to minimize any carryover effect.
Venous PK blood samples for PK analysis will be collected pre-dose and post-dose in each period.
Pfizer is the lead sponsor of 3,337 studies on the registry; 150 are open to participants now.
Of its 601 completed or terminated interventional studies of FDA-regulated products, 392 (65%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Ritlecitinib 100 mg solution (fasted, Period 1), followed by ritlecitinib 100 mg MR capsule 1 (fasted, Period 2), followed by ritlecitinib 100 mg MR capsule 2 (fasted, Period 3), and followed by ritlecitinib 100 mg MR capsule 1 (fed, Period 4)
Drug: Ritlecitinib
Ritlecitinib 100 mg MR capsule 1 (fasted, Period 1), followed by ritlecitinib 100 mg MR capsule 2 (fasted, Period 2), followed by ritlecitinib 100 mg solution (fasted, Period 3), and followed by ritlecitinib 100 mg MR capsule 1 (fed, Period 4)
Drug: Ritlecitinib
Ritlecitinib 100 mg MR capsule 2 (fasted, Period 1), followed by ritlecitinib 100 mg solution (fasted, Period 2), followed by ritlecitinib 100 mg MR capsule 1 (fasted, Period 3), and followed by ritlecitinib 100 mg MR capsule 1 (fed, Period 4)
Drug: Ritlecitinib
Ritlecitinib 100 mg solution (fasted, Period 1), followed by ritlecitinib 100 mg MR capsule 1 (fasted, Period 2), followed by ritlecitinib 100 mg MR capsule 2 (fasted, Period 3), and followed by ritlecitinib 100 mg MR capsule 2 (fed, Period 4)
Drug: Ritlecitinib
Ritlecitinib 100 mg MR capsule 1 (fasted, Period 1), followed by ritlecitinib 100 mg MR capsule 2 (fasted, Period 2), followed by ritlecitinib 100 mg solution (fasted, Period 3), and followed by ritlecitinib 100 mg MR capsule 2 (fed, Period 4)
Drug: Ritlecitinib
Ritlecitinib 100 mg MR capsule 2 (fasted, Period 1), followed by ritlecitinib 100 mg solution (fasted, Period 2), followed by ritlecitinib 100 mg MR capsule 1 (fasted, Period 3), and followed by ritlecitinib 100 mg MR capsule 2 (fed, Period 4)
Drug: Ritlecitinib
Ritlecitinib 100 milligrams (mg) will be provided as either solution or capsule formulation (2 capsules of 50 mg)
Also known as: PF-06651600
Maximum Observed Concentration (Cmax) of Ritlecitinib: MR Capsules vs Oral Solution Under Fasted Condition
Time frame: For oral solution: Pre-dose (0 hours), 0.5, 1, 2, 3, 4, 6, 10, 12 and 24 hours post-dose on Day 1 of Period 1, 2 or 3; for MR1 and MR2 capsules: Pre-dose (0 hours), 1, 2, 3, 4, 6, 10, 12,16, 24, 36 and 48 hours post-dose on Day 1 of Period 1, 2 or 3
Area Under the Plasma Concentration-Time Profile From Time Zero (0) Extrapolated to Infinite Time (AUCinf) of Ritlecitinib: MR Capsules vs Oral Solution Under Fasted Condition
AUCinf was calculated as AUClast + (Clast/kel), where Clast was the predicted plasma concentration at the last quantifiable time point from the log-linear regression analysis and kel was the terminal phase rate constant calculated by a linear regression of the log-linear concentration-time curve.
Time frame: For oral solution: Pre-dose (0 hours), 0.5, 1, 2, 3, 4, 6, 10, 12 and 24 hours post-dose on Day 1 of Period 1, 2 or 3; for MR1 and MR2 capsules: Pre-dose (0 hours), 1, 2, 3, 4, 6, 10, 12,16, 24, 36 and 48 hours post-dose on Day 1 of Period 1, 2 or 3
Cmax of Ritlecitinib: MR Capsules Under Fed vs Fasted Condition
Time frame: Pre-dose (0 hours), 1, 2, 3, 4, 6, 10, 12,16, 24, 36 and 48 hours post-dose on Day 1 of Period 1, 2, 3 (for fasted) or 4 (for fed)
AUCinf of Ritlecitinib: MR Capsules Under Fed vs Fasted Condition
AUCinf was calculated as AUClast + (Clast/kel), where Clast was the predicted plasma concentration at the last quantifiable time point from the log-linear regression analysis and kel was the terminal phase rate constant calculated by a linear regression of the log-linear concentration-time curve.
Time frame: Pre-dose (0 hours), 1, 2, 3, 4, 6, 10, 12,16, 24, 36 and 48 hours post-dose on Day 1 of Period 1, 2, 3 (for fasted) or 4 (for fed)
Number of Participants With Adverse Events (AEs)
An AE was any untoward medical occurrence in a participant temporally associated with the use of study intervention, whether or not considered related to the study intervention.
Time frame: From start of study treatment up to 35 days after administration of last dose of study intervention (maximum up to 45 days)
Number of Participants With Clinically Significant Laboratory Test Abnormalities
Laboratory parameters included: Hematology: lymphocytes/leukocytes, eosinophils/leukocytes greater than (\>) 1.2\*upper limit of normal (ULN) (percent \[%\]), neutrophils/leukocytes less than (\<) 0.8\*lower limit of normal (LLN) (%); Urinalysis: urine hemoglobin, nitrite greater than or equal to (\>=) 1, bacteria \> 20 (per high power field \[/HPF\]). Clinical significance was judged by investigator.
Time frame: From start of study treatment up to Day 3 of Period 4 (maximum up to Day 12, each Period = 3 days)
Number of Participants With Clinically Significant Vital Signs Abnormalities
Vital signs including systolic blood pressure (SBP), diastolic blood pressure (DBP) and pulse rate (PR) were measured in a supine position. Criteria for vital signs included: SBP: value less than (\<) 90 millimeter of mercury (mmHg), change greater than or equal to (\>=) 30 mmHg decrease, change \>= 30 mmHg increase; DBP: value \< 50 mmHg, change \>= 20 mmHg decrease, change \>= 20 mmHg increase; PR: value \< 40 beats per minute (bpm), value \> 120 bpm. Clinical significance was judged by investigator.
Time frame: From start of study treatment up to Day 3 of Period 4 (maximum up to Day 12, each Period = 3 days)
Number of Participants With Clinically Significant Electrocardiogram (ECG) Abnormalities
Standard 12 lead ECGs were obtained with the participant in a supine position after at least 5 minutes of rest using an ECG machine that automatically calculated the heart rate and measured PR interval, QT, corrected QT (Fridericia method) (QTcF) and QRS intervals. Clinical significance was judged by investigator.
Time frame: From start of study treatment up to Day 3 of Period 4 (maximum up to Day 12, each Period = 3 days)
| Milestone | Treatment Sequence 1: A Then B Then C Then B (Fed) | Treatment Sequence 2: B Then C Then A Then B (Fed) | Treatment Sequence 3: C Then A Then B Then B (Fed) | Treatment Sequence 4: A Then B Then C Then C (Fed) | Treatment Sequence 5: B Then C Then A Then C (Fed) | Treatment Sequence 6: C Then A Then B Then C (Fed) |
|---|---|---|---|---|---|---|
| Started | 2 | 2 | 2 | 2 | 2 | 2 |
| Completed | 2 | 2 | 2 | 2 | 2 | 2 |
| Not completed | 0 | 0 | 0 | 0 | 0 | 0 |
| Milestone | Treatment Sequence 1: A Then B Then C Then B (Fed) | Treatment Sequence 2: B Then C Then A Then B (Fed) | Treatment Sequence 3: C Then A Then B Then B (Fed) | Treatment Sequence 4: A Then B Then C Then C (Fed) | Treatment Sequence 5: B Then C Then A Then C (Fed) | Treatment Sequence 6: C Then A Then B Then C (Fed) |
|---|---|---|---|---|---|---|
| Started | 2 | 2 | 2 | 2 | 2 | 2 |
| Completed | 2 | 2 | 1 | 2 | 2 | 2 |
| Not completed | 0 | 0 | 1 | 0 | 0 | 0 |
| Withdrew: Adverse event | 0 | 0 | 1 | 0 | 0 | 0 |
| Milestone | Treatment Sequence 1: A Then B Then C Then B (Fed) | Treatment Sequence 2: B Then C Then A Then B (Fed) | Treatment Sequence 3: C Then A Then B Then B (Fed) | Treatment Sequence 4: A Then B Then C Then C (Fed) | Treatment Sequence 5: B Then C Then A Then C (Fed) | Treatment Sequence 6: C Then A Then B Then C (Fed) |
|---|---|---|---|---|---|---|
| Started | 2 | 2 | 1 | 2 | 2 | 2 |
| Completed | 2 | 2 | 1 | 2 | 2 | 2 |
| Not completed | 0 | 0 | 0 | 0 | 0 | 0 |
| Milestone | Treatment Sequence 1: A Then B Then C Then B (Fed) | Treatment Sequence 2: B Then C Then A Then B (Fed) | Treatment Sequence 3: C Then A Then B Then B (Fed) | Treatment Sequence 4: A Then B Then C Then C (Fed) | Treatment Sequence 5: B Then C Then A Then C (Fed) | Treatment Sequence 6: C Then A Then B Then C (Fed) |
|---|---|---|---|---|---|---|
| Started | 2 | 2 | 1 | 2 | 2 | 2 |
| Completed | 2 | 2 | 1 | 2 | 2 | 2 |
| Not completed | 0 | 0 | 0 | 0 | 0 | 0 |
| Nanogram per milliliter (ng/mL) | Ritlecitinib 100 mg Oral Solution (Fasted) | Ritlecitinib 100 mg MR1 Capsule (Fasted) | Ritlecitinib 100 mg MR2 Capsule (Fasted) |
|---|---|---|---|
| Maximum Observed Concentration (Cmax) of Ritlecitinib: MR Capsules vs Oral Solution Under Fasted Condition | 671.6 ± 24 | 145.1 ± 25 | 84.96 ± 25 |
AUCinf was calculated as AUClast + (Clast/kel), where Clast was the predicted plasma concentration at the last quantifiable time point from the log-linear regression analysis and kel was the terminal phase rate constant calculated by a linear regression of the log-linear concentration-time curve.
| Nanogram*Hour per milliliter (ng*hr/mL) | Ritlecitinib 100 mg Oral Solution (Fasted) | Ritlecitinib 100 mg MR1 Capsule (Fasted) | Ritlecitinib 100 mg MR2 Capsule (Fasted) |
|---|---|---|---|
| Area Under the Plasma Concentration-Time Profile From Time Zero (0) Extrapolated to Infinite Time (AUCinf) of Ritlecitinib: MR Capsules vs Oral Solution Under Fasted Condition | 1261 ± 23 | 1067 ± 28 | 970.6 ± 22 |
| Nanogram per milliliter (ng/mL) | Ritlecitinib 100 mg MR1 Capsule (Fasted) | Ritlecitinib 100 mg MR2 Capsule (Fasted) | Ritlecitinib 100 mg MR1 Capsule (Fed) | Ritlecitinib 100 mg MR2 Capsule (Fed) |
|---|---|---|---|---|
| Cmax of Ritlecitinib: MR Capsules Under Fed vs Fasted Condition | 145.1 ± 25 | 84.96 ± 25 | 177.1 ± 16 | 112.0 ± 14 |
AUCinf was calculated as AUClast + (Clast/kel), where Clast was the predicted plasma concentration at the last quantifiable time point from the log-linear regression analysis and kel was the terminal phase rate constant calculated by a linear regression of the log-linear concentration-time curve.
| Nanogram*Hour per milliliter (ng*hr/ mL) | Ritlecitinib 100 mg MR1 Capsule (Fasted) | Ritlecitinib 100 mg MR2 Capsule (Fasted) | Ritlecitinib 100 mg MR1 Capsule (Fed) | Ritlecitinib 100 mg MR2 Capsule (Fed) |
|---|---|---|---|---|
| AUCinf of Ritlecitinib: MR Capsules Under Fed vs Fasted Condition | 1067 ± 28 | 970.6 ± 22 | 1168 ± 20 | 1036 ± 15 |
An AE was any untoward medical occurrence in a participant temporally associated with the use of study intervention, whether or not considered related to the study intervention.
| Participants | Ritlecitinib 100 mg Oral Solution (Fasted) | Ritlecitinib 100 mg MR1 Capsule (Fasted) | Ritlecitinib 100 mg MR2 Capsule (Fasted) | Ritlecitinib 100 mg MR1 Capsule (Fed) | Ritlecitinib 100 mg MR2 Capsule (Fed) |
|---|---|---|---|---|---|
| Number of Participants With Adverse Events (AEs) | 3 | 5 | 3 | 0 | 1 |
Laboratory parameters included: Hematology: lymphocytes/leukocytes, eosinophils/leukocytes greater than (\>) 1.2\*upper limit of normal (ULN) (percent \[%\]), neutrophils/leukocytes less than (\<) 0.8\*lower limit of normal (LLN) (%); Urinalysis: urine hemoglobin, nitrite greater than or equal to (\>=) 1, bacteria \> 20 (per high power field \[/HPF\]). Clinical significance was judged by investigator.
| Participants | Ritlecitinib 100 mg Oral Solution (Fasted) | Ritlecitinib 100 mg MR1 Capsule (Fasted) | Ritlecitinib 100 mg MR2 Capsule (Fasted) | Ritlecitinib 100 mg MR1 Capsule (Fed) | Ritlecitinib 100 mg (MR2 Capsule) Fed |
|---|---|---|---|---|---|
| Number of Participants With Clinically Significant Laboratory Test Abnormalities | 0 | 0 | 0 | 0 | 0 |
Vital signs including systolic blood pressure (SBP), diastolic blood pressure (DBP) and pulse rate (PR) were measured in a supine position. Criteria for vital signs included: SBP: value less than (\<) 90 millimeter of mercury (mmHg), change greater than or equal to (\>=) 30 mmHg decrease, change \>= 30 mmHg increase; DBP: value \< 50 mmHg, change \>= 20 mmHg decrease, change \>= 20 mmHg increase; PR: value \< 40 beats per minute (bpm), value \> 120 bpm. Clinical significance was judged by investigator.
| Participants | Ritlecitinib 100 mg Oral Solution (Fasted) | Ritlecitinib 100 mg MR1 Capsule (Fasted) | Ritlecitinib 100 mg MR2 Capsule (Fasted) | Ritlecitinib 100 mg MR1 Capsule (Fed) | Ritlecitinib 100 mg (MR2 Capsule) Fed |
|---|---|---|---|---|---|
| Number of Participants With Clinically Significant Vital Signs Abnormalities | 0 | 0 | 0 | 0 | 0 |
Standard 12 lead ECGs were obtained with the participant in a supine position after at least 5 minutes of rest using an ECG machine that automatically calculated the heart rate and measured PR interval, QT, corrected QT (Fridericia method) (QTcF) and QRS intervals. Clinical significance was judged by investigator.
| Participants | Ritlecitinib 100 mg Oral Solution (Fasted) | Ritlecitinib 100 mg MR1 Capsule (Fasted) | Ritlecitinib 100 mg MR2 Capsule (Fasted) | Ritlecitinib 100 mg MR1 Capsule (Fed) | Ritlecitinib 100 mg MR2 Capsule (Fed) |
|---|---|---|---|---|---|
| Number of Participants With Clinically Significant Electrocardiogram (ECG) Abnormalities | 1 | 0 | 0 | 0 | 0 |
Collected over From start of study treatment up to 35 days after administration of last dose of study intervention (maximum up to 45 days). Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Ritlecitinib 100 mg Oral Solution (Fasted) | 0/12 (0%) | 0/12 (0%) | 3/12 (25%) |
| Ritlecitinib 100 mg MR1 Capsules (Fasted) | 0/11 (0%) | 0/11 (0%) | 5/11 (45.5%) |
| Ritlecitinib 100 mg MR2 Capsules (Fasted) | 0/12 (0%) | 0/12 (0%) | 3/12 (25%) |
| Ritlecitinib 100 mg MR1 Capsules (Fed) | 0/5 (0%) | 0/5 (0%) | 0/5 (0%) |
| Ritlecitinib 100 mg MR2 Capsules (Fed) | 0/6 (0%) | 0/6 (0%) | 1/6 (16.7%) |
| Event | Ritlecitinib 100 mg Oral Solution (Fasted) | Ritlecitinib 100 mg MR1 Capsules (Fasted) | Ritlecitinib 100 mg MR2 Capsules (Fasted) | Ritlecitinib 100 mg MR1 Capsules (Fed) | Ritlecitinib 100 mg MR2 Capsules (Fed) |
|---|---|---|---|---|---|
| HaematomaVascular disorders | 0/12 | 1/11 | 3/12 | 0/5 | 0/6 |
| ErythemaSkin and subcutaneous tissue disorders | 0/12 | 0/11 | 0/12 | 0/5 | 1/6 |
| Abdominal painGastrointestinal disorders | 0/12 | 1/11 | 0/12 | 0/5 | 0/6 |
| ChillsGeneral disorders | 0/12 | 1/11 | 0/12 | 0/5 | 0/6 |
| Pain in extremityMusculoskeletal and connective tissue disorders | 0/12 | 1/11 | 0/12 | 0/5 | 0/6 |
| Night sweatsSkin and subcutaneous tissue disorders | 0/12 | 1/11 | 0/12 | 0/5 | 0/6 |
| PruritusSkin and subcutaneous tissue disorders | 0/12 | 1/11 | 0/12 | 0/5 | 0/6 |
| Atrioventricular block first degreeCardiac disorders | 1/12 | 0/11 | 0/12 | 0/5 | 0/6 |
| DiarrhoeaGastrointestinal disorders | 0/12 | 0/11 | 1/12 | 0/5 | 0/6 |
| Vessel puncture site painGeneral disorders | 1/12 | 0/11 | 0/12 | 0/5 | 0/6 |
| Age, Categorical(Participants) | Treatment Sequence 1: A Then B Then C Then B (Fed) | Treatment Sequence 2: B Then C Then A Then B (Fed) | Treatment Sequence 3: C Then A Then B Then B (Fed) | Treatment Sequence 4: A Then B Then C Then C (Fed) | Treatment Sequence 5: B Then C Then A Then C (Fed) | Treatment Sequence 6: C Then A Then B Then C (Fed) | Total |
|---|---|---|---|---|---|---|---|
| <=18 years | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Between 18 and 65 years | 2 | 2 | 1 | 2 | 1 | 2 | 10 |
| >=65 years | 0 | 0 | 1 | 0 | 1 | 0 | 2 |
| Sex: Female, Male(Participants) | Treatment Sequence 1: A Then B Then C Then B (Fed) | Treatment Sequence 2: B Then C Then A Then B (Fed) | Treatment Sequence 3: C Then A Then B Then B (Fed) | Treatment Sequence 4: A Then B Then C Then C (Fed) | Treatment Sequence 5: B Then C Then A Then C (Fed) | Treatment Sequence 6: C Then A Then B Then C (Fed) | Total |
|---|---|---|---|---|---|---|---|
| Female | 0 | 0 | 0 | 1 | 0 | 0 | 1 |
| Male | 2 | 2 | 2 | 1 | 2 | 2 | 11 |
| Ethnicity (NIH/OMB)(Participants) | Treatment Sequence 1: A Then B Then C Then B (Fed) | Treatment Sequence 2: B Then C Then A Then B (Fed) | Treatment Sequence 3: C Then A Then B Then B (Fed) | Treatment Sequence 4: A Then B Then C Then C (Fed) | Treatment Sequence 5: B Then C Then A Then C (Fed) | Treatment Sequence 6: C Then A Then B Then C (Fed) | Total |
|---|---|---|---|---|---|---|---|
| Hispanic or Latino | 0 | 0 | 0 | 0 | 0 | 1 | 1 |
| Not Hispanic or Latino | 2 | 2 | 1 | 2 | 2 | 1 | 10 |
| Unknown or Not Reported | 0 | 0 | 1 | 0 | 0 | 0 | 1 |
| Race (NIH/OMB)(Participants) | Treatment Sequence 1: A Then B Then C Then B (Fed) | Treatment Sequence 2: B Then C Then A Then B (Fed) | Treatment Sequence 3: C Then A Then B Then B (Fed) | Treatment Sequence 4: A Then B Then C Then C (Fed) | Treatment Sequence 5: B Then C Then A Then C (Fed) | Treatment Sequence 6: C Then A Then B Then C (Fed) | Total |
|---|---|---|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Asian | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Black or African American | 0 | 0 | 1 | 1 | 1 | 1 | 4 |
| White | 2 | 2 | 1 | 1 | 1 | 1 | 8 |
| More than one race | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No — Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.
Ran from Feb 2024 to primary completion in Mar 2024, 1 month.
Results were first posted in Apr 2025, 1 year after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Mar 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: PF-06651600